1963—Nalidixic acid is approved by Food and Drug Administration for treatment of urinary tract infections.
1980s—Modifications made to nalidixic acid, resulting in fluoroquinolone antimicrobial drugs such as Tequin.
December 1999—Bristol-Myers receives fast track for FDA approval of Tequin (minus premarket testing to determine possible side effects). The drug would generate about $150 million in sales for each of the next six years.
2002—Information added to Tequin’s label about risks of high and low blood sugar.
2002—Pharmacists fill 3 million prescriptions for Tequin.
2005—400 complaints about blood sugar changes, 159 hospitalizations and 20 deaths attributed to use of Tequin since it went on market.
February 15, 2006—FDA urges Bristol-Myers Squibb to revise its labeling of Tequin due to dangerous health risks, still stopping short of a complete recall.
March 2006—The New England Journal of Medicine publishes article about heightened dangers for elderly patients taking Tequin.
May 1, 2006—Bristol-Myers Squibb announces it will no longer make and sell Tequin.
May 2, 2006—Consumer watchdog group Public Citizen petitions FDA to ban Tequin.
May 9, 2006—$200,000 class action lawsuit filed in Canada, alleging Bristol-Myers Squibb did not properly inform patients of risks of Tequin.